- Price
- $88.38
- Day
- +5.40%
- Mkt Cap
- $7.86B
- 52W Range
- $19.02 – $91.10
- Volume
- 1.07M
- Beta
- 0.55
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.
Read full article
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Read full article
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
Read full article
Liquidia, Energy Transfer and PBF Energy offer low-beta exposure as oil-driven volatility rises, backed by growth, stable fees and refining demand.
Read full article
Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.
Read full article